Ligand Pharmaceuticals Incorporated (FRA:LGDN)

Germany flag Germany · Delayed Price · Currency is EUR
167.00
-5.00 (-2.91%)
At close: Dec 1, 2025
45.22%
Market Cap3.45B
Revenue (ttm)214.13M
Net Income (ttm)41.41M
Shares Outn/a
EPS (ttm)2.12
PE Ratio83.29
Forward PE29.73
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volumen/a
Open171.00
Previous Close172.00
Day's Range167.00 - 171.00
52-Week Range86.00 - 181.00
Betan/a
RSI49.18
Earnings DateFeb 11, 2026

About Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI, a dual endothelin and angiotensin II receptor antagonist for immunoglobulin A nephropathy; Ohtuvayre for respiratory disease; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neurobla... [Read more]

Industry Pharmaceutical Preparations
Founded 1987
Employees 68
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol LGDN
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

There is no news available yet.